Pelthos Therapeutics Inc.
Pelthos Therapeutics Inc. (NASDAQ: PTHS) is a biopharmaceutical company committed to commercializing innovative therapeutic products addressing unmet treatment needs in dermatology and pain management. The company operates through its commercial product portfolio and manufacturing operations, with its primary website… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Pelthos Therapeutics Inc. does
In the company’s own words
Pelthos Therapeutics Inc. (NASDAQ: PTHS) is a biopharmaceutical company committed to commercializing innovative therapeutic products addressing unmet treatment needs in dermatology and pain management. The company operates through its commercial product portfolio and manufacturing operations, with its primary website at pelthos.com.
The company's commercial portfolio includes three FDA-approved products in various stages of commercialization. ZELSUVMI, a topical gel containing berdazimer sodium, is indicated for treating molluscum contagiosum in patients one year and older and represents the first FDA-approved at-home prescription medication for this viral skin infection that can be administered by patients and caregivers outside medical settings. XEPI, a non-fluorinated quinolone antimicrobial cream, treats impetigo caused by Staphylococcus aureus or Streptococcus pyogenes in patients two months and older. XEGLYZE, a pediculicide containing abametapir, addresses head lice infestation in patients six months and older.
Pelthos was effectively formed on July 1, 2025, through the merger of Channel Therapeutics Corporation and LNHC, Inc., a subsidiary of Ligand Pharmaceuticals that held assets acquired from Novan, Inc. This transaction provided the company with ZELSUVMI, the proprietary NITRICIL technology platform, and a manufacturing facility in Durham, North Carolina. The NITRICIL platform leverages nitric oxide's naturally occurring anti-viral, anti-bacterial, anti-fungal, and immunomodulatory properties to develop differentiated product candidates.
Beyond its commercial products, Pelthos maintains clinical-stage assets targeting NaV1.7 sodium ion-channels for pain management, including programs for eye pain, post-operative pain via nerve blocks, and neuropathic pain conditions. The company manufactures the active pharmaceutical ingredient berdazimer sodium at its Durham facility and partners with third-party manufacturers for finished product production and distribution through retail pharmacy chains, mail order pharmacies, and online platforms.
The company operates as a smaller reporting company and is classified as a non-accelerated filer. Pelthos faces significant competition in dermatology and maintains exclusive licensing agreements with Ligand for ZELSUVMI commercialization rights worldwide except Japan, while also operating a master services agreement for API supply to Ligand and potential third-party licensees.
Company details
- Sector
- Healthcare
- Industry
- Biological Products
- Headquarters
- DURHAM, NC
- Fiscal year end
- December
- CIK
- 1919246
- SIC
- 2836
Financial performance, year by year
Fiscal 2023–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Pelthos Therapeutics Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Pelthos Therapeutics Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Pelthos Therapeutics Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Pelthos Therapeutics Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Pelthos Therapeutics Inc.'s last four quarterly filings that the numbers alone won't show?”